Table 2.
Demographic and baseline parameters of the study population
| Parameter | CVVHD—citrate | CVVHDF—heparin | p value |
|---|---|---|---|
| Number of patients (n) | 60 | 50 | |
| Gender (n, male) | 44 (73 %) | 36 (72 %) | n.s. |
| Age (years) | 68 ± 12 | 69 ± 11 | n.s. |
| Bodyweight (kg) | 87 ± 21 | 86 ± 23 | n.s. |
| Sepsis (n) | 16 (27 %) | 16 (32 %) | n.s. |
| Postoperative (n) | 40 (66 %) | 25 (50 %) | n.s. |
| Other reason for ICU admission (n) | 4 (7 %) | 9 (18 %) | n.s. |
| SOFA score at initiation of CRRT | 10 ± 3 | 9 ± 3 | n.s. |
| Creatinine before present illness (μmol/l) | 195 ± 139 | 226 ± 252 | n.s. |
| Creatinine at initiation of CRRT (μmol/l) | 337 ± 133 | 343 ± 179 | n.s. |
| Urea before present illness (mmol/l) | 11 ± 9 | 10 ± 9 | n.s. |
| Urea at initiation of CRRT (mmol/l) | 23 ± 9 | 22 ± 9 | n.s. |
| Mean platelet count during CRRT (G/l) | 168 ± 108 | 175 ± 115 | n.s. |
| Mean dose of CRRT (ml∙h−1∙kg body weight−1) | 24.0 ± 6.2 | 20.7 ± 5.6 | 0.0001 |
| Mean blood flow (ml/min) | 102 ± 12.5 | 100 ± 2.8 | n.s. |
| Mean dialysate flow (ml/h) | 2035 ± 307 | 1133 ± 283 | 0.0001 |
| Mean flow replacement fluid (ml/h) | – | 563 ± 203 | n.a. |
| Mean ultrafiltration flow (ml/h) | 159 ± 55 | 170 ± 59 | 0.0001 |
| Mechanical ventilation (n) | 43 (72 %) | 40 (80 %) | n.s. |
| Cirrhosis of the liver (n) | 6 (10 %) | 4 (8 %) | n.s. |
| Patients weaned from CRRT (n) | 22 (37 %) | 19 (38 %) | n.s. |
| Patients receiving intermittent dialysis at ICU discharge (n) | 8 (13 %) | 4 (8 %) | n.s. |
| Fatal outcome on ICU (n) | 30 (50 %) | 27 (54 %) | n.s. |
CRRT continuous renal replacement therapy, CVVHDF continuous veno-venous haemodiafiltration, CVVHD continuous veno-venous haemodialysis, SOFA Sequential Organ Failure Assessment, ICU intensive care unit, n.s. not significant, n.a. not applicable